The plasma soluble MCAM levels of NSCLC patients are significantly higher than those of healthy subjects, and are significantly associated with shorter progression-free survival and overall survival [8]; however, the role of MCAM in lung adenocarcinoma patients with EGFR mutations still remains to be explored. This evidence concerns the gene MCAM and non-small cell lung carcinoma.